Key Findings from the 2025 Global Compliance Survey

Our survey of 120 QA, QC, and risk executives across pharma, biotech, and CDMOs reveals:

1. 72% cite data integrity gaps as the #1 inspection risk. Paper-hybrid systems and inconsistent audit trails remain widespread.
2. 65% highlight uncertainty in applying AI/ML under GxP. Most firms lack structured validation or monitoring frameworks.
3. 59% of CDMOs report that client audit frequency has increased by >25% since 2020. Audit scope is also broader, covering digital and vendor systems.
4. 41% of respondents still use paper batch records in at least one facility, despite regulators' urging for digitisation.
5. Seventy-four per cent believe digital audit readiness will become a board-level mandate within two years.
6. Only 18% run a validated AI governance framework (GMLP) — exposing them to risk of unexplainable system outputs.

• Rising enforcement: FDA warning letters increased 25% from 2020–2024, with data integrity cited in >60% of cases [FDA, 2024].
• Regulatory tightening: EMA and CDSCO have both issued new expectations on AI/ML transparency and digital records.
• Economic stakes: Cost of a single consent decree can exceed $500M (public cases), while digital-first programs often yield 2x ROI through avoided penalties and efficiency gains.

Bottom line: Leaders who invest now can position compliance as both a risk shield and growth enabler.

Drivers of Change

• Complex global supply chains

• Faster speed-to-market demands

• Data volumes exploding

• Rising regulatory scrutiny

• AI adoption pressure

Survey Methodology & Respondent Profile

• Pharma Segment Priorities

• Biotech Segment Challenges

• CDMO Segment Needs

• Digital QMS Adoption Trends

Key Regulatory Frameworks

• FDA 21 CFR Part 11 (Electronic Records & Signatures): Foundational requirement for trust in digital records.
• EU Annexe 11 (EMA, Computerised Systems): Emphasis on validation, security, and audit trails.
• ICH Q9 (R1, effective July 2023): Enhanced risk management, with explicit mention of digital systems.
• CSA (Computer Software Assurance, FDA draft 2024): Shifts validation to a risk-based approach — focus on intended use, not documentation volume.

• CDSCO India (2023 Guidance): Push for electronic batch records and audit trails in manufacturing sites.

   

Recent Regulatory Announcements (Timeline)

Business Challenges in Achieving Digital-First Compliance

Our 2025 survey and interviews reveal six recurring barriers that slow digital-first, audit-ready compliance adoption across pharma, biotech, and CDMOs

• Fragmented Legacy Systems
• Validation Burden (CSV/CSA Transition)

• Resource & Capability Constraints
• Vendor Oversight & Cloud Qualification

• AI/ML Governance Ambiguity
• Change Resistance & Culture

Context & Pain Points

• Top-10 pharma, 50+ manufacturing sites worldwide.

• 3 FDA 483s in 2 years citing data integrity & audit trail gaps.

• Hybrid paper-digital processes; partial LIMS, manual batch release.

• Rising risk after competitor’s $600M consent decree.

Solution Implemented

Digital-first compliance transformation led by a cross-functional task force.

• Consolidated 8 legacy LIMS systems
• Adopted Computer Software Assurance

• Established central AI Governance Board
• Deployed a real-time compliance dashboard

Timeline & Maturity

• Year 1: Pilots in 2 sites, eQMS roll-out, CSA training.
• Year 2: Global LIMS consolidation, compliance dashboard deployed.

• Year 3: AI-assisted QC anomaly detection system validated under GMLP principles.

   

Context & Pain Points

• CDMO Scale

• Revenue Risk

• Operational Gaps

• Client Demands

Timeline & Maturity

• Months 1–6: eQMS go-live, training completed.

• Months 6–12: AI deviation pilot in QC.

• Year 2: Expansion to document management and training records.

Measured Outcomes